Results 1 to 10 of about 482,699 (357)

Addressing current challenges in cancer immunotherapy with mathematical and computational modeling [PDF]

Journal of the Royal Society Interface, 14 (131): 20170150 (2017), 2017
The goal of cancer immunotherapy is to boost a patient's immune response to a tumor. Yet, the design of an effective immunotherapy is complicated by various factors, including a potentially immunosuppressive tumor microenvironment, immune-modulating effects of conventional treatments, and therapy-related toxicities.
Adler, Adam J., Konstorum, Anna, Laubenbacher, Reinhard, Vella, Anthony T.   +3 more
arxiv   +3 more sources

The inter-link of ageing, cancer and immunity: findings from real-world retrospective study

Immunity & Ageing, 2023
Background Although the concept of declined immune function associated with cancer has been accepted extensively, real-world clinical studies focusing on analysis of the peripheral blood immune changes underlying ageing, immunity and cancer are scarce ...
Xiaomin Fu, Peng Qin, Fanghui Li, Huifang Zhu, Hongqin You, Yong Zhang, Benling Xu, Tiepeng Li, Fang Zhang, Lu Han, Lingdi Zhao, Baozhen Ma, Zibing Wang, Quanli Gao   +13 more
doaj   +1 more source

Exhaustion of CAR T cells: potential causes and solutions

Journal of Translational Medicine, 2022
Chimeric antigen receptor (CAR) T cell therapy has attracted attention for its promising therapeutic effects on hematological malignancies. However, there are problems such as relapse during long-term follow-up and limited effect on solid tumors with ...
Taku Kouro, Hidetomo Himuro, Tetsuro Sasada   +2 more
doaj   +1 more source

Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity

OncoImmunology, 2021
Cancer-associated fibroblasts (CAFs) and hypoxia are central players in the complex process of tumor cell-stroma interaction and are involved in the alteration of the anti-tumor immune response by impacting both cancer and immune cell populations ...
Linda Ziani, Stéphanie Buart, Salem Chouaib, Jerome Thiery   +3 more
doaj   +1 more source

Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature

BMC Gastroenterology, 2021
Background Colorectal cancer (CRC) is the third most prevalent cancer worldwide and poses a serious challenge for clinicians. Previous studies have shown promising results in patients with Microsatellite Stable microsatellite-stable CRC refractory to ...
Yong Zhang, Fang Zhang, Lingdi Zhao, Xiaomin Fu, Yiman Shang, Quanli Gao   +5 more
doaj   +1 more source

High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study

Frontiers in Immunology, 2022
Background and ObjectiveThe results of the CheckMate 025 trial established the status of nivolumab in the second-line treatment of metastatic renal cell carcinoma (mRCC), with an objective response rate (ORR) of 25% and a complete response (CR) rate of 1%
Lingdi Zhao, Tiepeng Li, Yongping Song, Yonghao Yang, Baozhen Ma, Yong Zhang, Yiman Shang, Benling Xu, Jindong Guo, Peng Qin, Lu Han, Xiaomin Fu, Hongwei Lin, Liang Liu, Xiubao Ren, Zibing Wang, Quanli Gao   +16 more
doaj   +1 more source

Immunotherapy of cancer [PDF]

European Journal of Pharmacology, 2009
Major advances have been made in the field of immunology in the past two decades. A better understanding of the molecular and cellular mechanisms controlling the immune system has opened the door to many innovative and promising new cancer therapies that manipulate the immune response.
Kerry S. Campbell, Hossein Borghaei, Mitchell R. Smith   +2 more
openaire   +3 more sources

Biomarkers in Cancer Immunotherapy [PDF]

Cancer Cell, 2015
Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer ...
Schumacher, Ton N, Kesmir, Can, van Buuren, Marit M   +2 more
openaire   +4 more sources

The Evolution of Cancer Immunotherapy [PDF]

Vaccines, 2021
Immunotherapy has changed the environment of cancer treatment by providing new and efficacious therapy options for many solid and hematologic malignancies. Although not a new field of oncology, immunotherapy has quickly developed into one of the most flourishing fields in medicine.
Meshaal Khan, Ajay V. Maker, Shikha Jain
openaire   +6 more sources

Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer

Scientific Reports, 2021
Despite recent progress in therapeutic strategies, prognosis of metastatic triple-negative breast cancer (TNBC) remains dismal. Evidence suggests that the induction and activation of tumor-residing conventional type-1 dendritic cells (cDC1s) is critical ...
Toshihiro Yokoi, Takaaki Oba, Ryutaro Kajihara, Scott I. Abrams, Fumito Ito   +4 more
doaj   +1 more source